12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Other News

Cleveland BioLabs, U.S. Department of Health and Human Services (HHS) other news

Cleveland BioLabs submitted a proposal to HHS's Biomedical Advanced Research and Development Authority (BARDA) to fund the remaining development steps needed for FDA approval of entolimod ( CBLB502) as a medical radiation countermeasure. Cleveland BioLabs said the scope of the proposal is based on FDA feedback and is intended to address points noted by BARDA relating to Cleveland BioLabs' previous proposal.

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >